Identifying Better Outcome Measures to Improve Treatment of Agitation in Dementia

A Report from the EU/US/CTAD Task Force

M. Sano, M. Soto, M. Carrillo, J. Cummings, S. Hendrix, J. Mintzer, A. Porsteinsson, P. Rosenberg, L. Schneider, J. Touchon, P. Aisen, B. Vellas, Constantine G Lyketsos

Research output: Contribution to journalArticle

Abstract

For the second time in the past 3 years, the EU-US CTAD Task Force addressed challenges related to designing clinical trials for agitation in dementia, which is one of the most disruptive aspects of the condition for both patients and caregivers. Six recommendations emerged from the Task Force meeting: 1 - Operationalizing agitation criteria established by the IPA; 2 - Combining clinician- and caregiver-derived outcomes as primary outcome measures; 3 - Using global ratings to define clinically meaningful effects and power studies; 4 - Improving the accuracy of caregiver reports by better training and education of caregivers; 5 - Employing emerging technologies to collect near real-time behavioral data; and 6 - Utilizing innovative trial designs and increasing the use of biomarkers to maximize the productivity of clinical trials for neuropsychiatric symptoms.

Original languageEnglish (US)
Pages (from-to)98-102
Number of pages5
JournalThe journal of prevention of Alzheimer's disease
Volume5
Issue number2
DOIs
StatePublished - Jan 1 2018

Fingerprint

Advisory Committees
Caregivers
Dementia
Outcome Assessment (Health Care)
Clinical Trials
Therapeutics
Biomarkers
Technology
Education

Keywords

  • agitation
  • Alzheimer’s disease
  • clinical trials
  • dementia
  • Neuropsychiatric symptoms
  • NPS outcome measures

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Identifying Better Outcome Measures to Improve Treatment of Agitation in Dementia : A Report from the EU/US/CTAD Task Force. / Sano, M.; Soto, M.; Carrillo, M.; Cummings, J.; Hendrix, S.; Mintzer, J.; Porsteinsson, A.; Rosenberg, P.; Schneider, L.; Touchon, J.; Aisen, P.; Vellas, B.; Lyketsos, Constantine G.

In: The journal of prevention of Alzheimer's disease, Vol. 5, No. 2, 01.01.2018, p. 98-102.

Research output: Contribution to journalArticle

Sano, M, Soto, M, Carrillo, M, Cummings, J, Hendrix, S, Mintzer, J, Porsteinsson, A, Rosenberg, P, Schneider, L, Touchon, J, Aisen, P, Vellas, B & Lyketsos, CG 2018, 'Identifying Better Outcome Measures to Improve Treatment of Agitation in Dementia: A Report from the EU/US/CTAD Task Force', The journal of prevention of Alzheimer's disease, vol. 5, no. 2, pp. 98-102. https://doi.org/10.14283/jjpad.2018.15
Sano, M. ; Soto, M. ; Carrillo, M. ; Cummings, J. ; Hendrix, S. ; Mintzer, J. ; Porsteinsson, A. ; Rosenberg, P. ; Schneider, L. ; Touchon, J. ; Aisen, P. ; Vellas, B. ; Lyketsos, Constantine G. / Identifying Better Outcome Measures to Improve Treatment of Agitation in Dementia : A Report from the EU/US/CTAD Task Force. In: The journal of prevention of Alzheimer's disease. 2018 ; Vol. 5, No. 2. pp. 98-102.
@article{8726366cd3524be48206fd9f1b4ba27f,
title = "Identifying Better Outcome Measures to Improve Treatment of Agitation in Dementia: A Report from the EU/US/CTAD Task Force",
abstract = "For the second time in the past 3 years, the EU-US CTAD Task Force addressed challenges related to designing clinical trials for agitation in dementia, which is one of the most disruptive aspects of the condition for both patients and caregivers. Six recommendations emerged from the Task Force meeting: 1 - Operationalizing agitation criteria established by the IPA; 2 - Combining clinician- and caregiver-derived outcomes as primary outcome measures; 3 - Using global ratings to define clinically meaningful effects and power studies; 4 - Improving the accuracy of caregiver reports by better training and education of caregivers; 5 - Employing emerging technologies to collect near real-time behavioral data; and 6 - Utilizing innovative trial designs and increasing the use of biomarkers to maximize the productivity of clinical trials for neuropsychiatric symptoms.",
keywords = "agitation, Alzheimer’s disease, clinical trials, dementia, Neuropsychiatric symptoms, NPS outcome measures",
author = "M. Sano and M. Soto and M. Carrillo and J. Cummings and S. Hendrix and J. Mintzer and A. Porsteinsson and P. Rosenberg and L. Schneider and J. Touchon and P. Aisen and B. Vellas and Lyketsos, {Constantine G}",
year = "2018",
month = "1",
day = "1",
doi = "10.14283/jjpad.2018.15",
language = "English (US)",
volume = "5",
pages = "98--102",
journal = "The journal of prevention of Alzheimer's disease",
issn = "2426-0266",
publisher = "Springer International Publishing AG",
number = "2",

}

TY - JOUR

T1 - Identifying Better Outcome Measures to Improve Treatment of Agitation in Dementia

T2 - A Report from the EU/US/CTAD Task Force

AU - Sano, M.

AU - Soto, M.

AU - Carrillo, M.

AU - Cummings, J.

AU - Hendrix, S.

AU - Mintzer, J.

AU - Porsteinsson, A.

AU - Rosenberg, P.

AU - Schneider, L.

AU - Touchon, J.

AU - Aisen, P.

AU - Vellas, B.

AU - Lyketsos, Constantine G

PY - 2018/1/1

Y1 - 2018/1/1

N2 - For the second time in the past 3 years, the EU-US CTAD Task Force addressed challenges related to designing clinical trials for agitation in dementia, which is one of the most disruptive aspects of the condition for both patients and caregivers. Six recommendations emerged from the Task Force meeting: 1 - Operationalizing agitation criteria established by the IPA; 2 - Combining clinician- and caregiver-derived outcomes as primary outcome measures; 3 - Using global ratings to define clinically meaningful effects and power studies; 4 - Improving the accuracy of caregiver reports by better training and education of caregivers; 5 - Employing emerging technologies to collect near real-time behavioral data; and 6 - Utilizing innovative trial designs and increasing the use of biomarkers to maximize the productivity of clinical trials for neuropsychiatric symptoms.

AB - For the second time in the past 3 years, the EU-US CTAD Task Force addressed challenges related to designing clinical trials for agitation in dementia, which is one of the most disruptive aspects of the condition for both patients and caregivers. Six recommendations emerged from the Task Force meeting: 1 - Operationalizing agitation criteria established by the IPA; 2 - Combining clinician- and caregiver-derived outcomes as primary outcome measures; 3 - Using global ratings to define clinically meaningful effects and power studies; 4 - Improving the accuracy of caregiver reports by better training and education of caregivers; 5 - Employing emerging technologies to collect near real-time behavioral data; and 6 - Utilizing innovative trial designs and increasing the use of biomarkers to maximize the productivity of clinical trials for neuropsychiatric symptoms.

KW - agitation

KW - Alzheimer’s disease

KW - clinical trials

KW - dementia

KW - Neuropsychiatric symptoms

KW - NPS outcome measures

UR - http://www.scopus.com/inward/record.url?scp=85061764217&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061764217&partnerID=8YFLogxK

U2 - 10.14283/jjpad.2018.15

DO - 10.14283/jjpad.2018.15

M3 - Article

VL - 5

SP - 98

EP - 102

JO - The journal of prevention of Alzheimer's disease

JF - The journal of prevention of Alzheimer's disease

SN - 2426-0266

IS - 2

ER -